Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
THE BEST BLACK FRIDAY DEAL YET (Ad)
Airbnb has a plan to fix cleaning fees
Saudi viewers angry over apparent ban on World Cup streaming
THE BEST BLACK FRIDAY DEAL YET (Ad)
Walmart shooting claims teen, young woman, father, mother
Cuba's informal market finds new space on growing internet
THE BEST BLACK FRIDAY DEAL YET (Ad)
Bird flu prompts slaughter of 1.8M chickens in Nebraska
US-England World Cup game seen by 19.98M on US television
NASDAQ:VCYT

Veracyte - VCYT Stock Forecast, Price & News

$26.20
-0.22 (-0.83%)
(As of 11/25/2022 08:58 PM ET)
Add
Compare
Today's Range
$25.49
$26.25
50-Day Range
$15.31
$29.94
52-Week Range
$14.85
$45.58
Volume
217,900 shs
Average Volume
958,190 shs
Market Capitalization
$1.88 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.17

Veracyte MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
34.2% Upside
$35.17 Price Target
Short Interest
Healthy
5.30% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.94
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$207,014 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.66) to ($0.57) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.58 out of 5 stars

Medical Sector

185th out of 1,044 stocks

Medical Laboratories Industry

7th out of 25 stocks

VCYT stock logo

About Veracyte (NASDAQ:VCYT) Stock

Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

VCYT Stock News Headlines

Veracyte Third Quarter 2022 Earnings: Beats Expectations
Veracyte: The FDA Is Stepping In
Veracyte (NASDAQ: VCYT)
See More Headlines
Receive VCYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter.

VCYT Company Calendar

Last Earnings
11/09/2021
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCYT
Employees
761
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$35.17
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$22.00
Forecasted Upside/Downside
+34.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-75,560,000.00
Pretax Margin
-15.62%

Debt

Sales & Book Value

Annual Sales
$219.51 million
Book Value
$14.61 per share

Miscellaneous

Free Float
69,672,000
Market Cap
$1.88 billion
Optionable
Optionable
Beta
1.28

Key Executives

  • Ms. Bonnie H. AndersonMs. Bonnie H. Anderson (Age 64)
    Co-Founder & Exec. Chairwoman
    Comp: $1.21M
  • Mr. Marc A. StapleyMr. Marc A. Stapley (Age 52)
    CEO & Director
    Comp: $900.4k
  • Ms. Rebecca ChambersMs. Rebecca Chambers (Age 44)
    Exec. VP & CFO
    Comp: $607.65k
  • Dr. Giulia C. Kennedy Ph.D. (Age 63)
    Global Chief Scientific Officer & Chief Medical Officer
    Comp: $691.33k
  • Dr. Tina S. Nova Ph.D. (Age 68)
    Pres of CLIA U.S. Bus.
    Comp: $4.58k
  • Ms. Beverly Jane Alley CPA (Age 59)
    VP & Corp. Controller
    Comp: $398.01k
  • Mr. Jonathan Wygant (Age 51)
    VP & Chief Accounting Officer
  • Mr. Steven French
    Sr. VP & Chief Information Officer
  • Ms. Annie McGuire (Age 42)
    Sr. VP & Gen. Counsel
  • Ms. Tracy Morris
    VP of Global Corp. Communications













VCYT Stock - Frequently Asked Questions

Should I buy or sell Veracyte stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last year. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VCYT shares.
View VCYT analyst ratings
or view top-rated stocks.

What is Veracyte's stock price forecast for 2023?

6 analysts have issued 12-month price objectives for Veracyte's shares. Their VCYT share price forecasts range from $22.00 to $50.00. On average, they predict the company's share price to reach $35.17 in the next twelve months. This suggests a possible upside of 34.2% from the stock's current price.
View analysts price targets for VCYT
or view top-rated stocks among Wall Street analysts.

How have VCYT shares performed in 2022?

Veracyte's stock was trading at $41.20 at the beginning of 2022. Since then, VCYT stock has decreased by 36.4% and is now trading at $26.20.
View the best growth stocks for 2022 here
.

When is Veracyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our VCYT earnings forecast
.

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) announced its quarterly earnings data on Tuesday, November, 9th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.14) by $0.06. The biotechnology company earned $60.37 million during the quarter, compared to the consensus estimate of $54.66 million. Veracyte had a negative net margin of 15.25% and a negative trailing twelve-month return on equity of 4.03%. During the same quarter last year, the company earned ($0.08) earnings per share.

What guidance has Veracyte issued on next quarter's earnings?

Veracyte updated its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $288.00 million-$293.00 million, compared to the consensus revenue estimate of $277.79 million.

What other stocks do shareholders of Veracyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO).

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

Who are Veracyte's major shareholders?

Veracyte's stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (12.69%), Vanguard Group Inc. (9.42%), BlackRock Inc. (8.58%), State Street Corp (7.28%), Artisan Partners Limited Partnership (5.31%) and Sumitomo Mitsui Trust Holdings Inc. (4.20%). Insiders that own company stock include Bonnie H Anderson, Evan/ Fa Jones, Giulia C Kennedy, Giulia C Kennedy, Jens Holstein, John Walter Hanna Jr, John Walter Hanna, Jr, Karin Eastham, Keith Kennedy, Kevin K Gordon, Marc Stapley, Mark Ho and Robert S Epstein.
View institutional ownership trends
.

How do I buy shares of Veracyte?

Shares of VCYT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veracyte's stock price today?

One share of VCYT stock can currently be purchased for approximately $26.20.

How much money does Veracyte make?

Veracyte (NASDAQ:VCYT) has a market capitalization of $1.88 billion and generates $219.51 million in revenue each year. The biotechnology company earns $-75,560,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.

How many employees does Veracyte have?

The company employs 761 workers across the globe.

How can I contact Veracyte?

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.veracyte.com. The biotechnology company can be reached via phone at (650) 243-6300, via email at keith@veracyte.com, or via fax at 650-243-6301.

This page (NASDAQ:VCYT) was last updated on 11/28/2022 by MarketBeat.com Staff